<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03564912</url>
  </required_header>
  <id_info>
    <org_study_id>ZhejiangU020</org_study_id>
    <nct_id>NCT03564912</nct_id>
  </id_info>
  <brief_title>Prospective Study on the Efficacy and Safety of 2 Week or 3 Week Xelox Regimen for Adjuvant Chemotherapy in CRC</brief_title>
  <official_title>Prospective Study on the Efficacy and Safety of 2 Week or 3 Week Xelox Regimen for Adjuvant Chemotherapy in Colorectal Patients After Surgery</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Zhejiang University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Zhejiang University</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study select the diagnosis of postoperative colorectal cancer patients with stage II/III&#xD;
      to adjuvant chemotherapy, and received 2 weeks and 3 weeks xelox adjuvant treatment process&#xD;
      until disease progression or patients died or lost to follow-up. To analyze the difference in&#xD;
      efficacy and safety of xelox in 2 weeks and 3 weeks of postoperative adjuvant therapy for&#xD;
      colorectal cancer, so as to find a better postoperative adjuvant treatment model.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">August 12, 2018</start_date>
  <completion_date type="Actual">August 24, 2021</completion_date>
  <primary_completion_date type="Actual">August 24, 2021</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>DFS</measure>
    <time_frame>through study completion, an average of 1 year</time_frame>
    <description>disease free survival</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of participants with treatment-related adverse events as assessed by CTCAE v4.0</measure>
    <time_frame>2 weeks</time_frame>
    <description>toxicity difference of two groups</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">160</enrollment>
  <condition>Colorectal Cancer</condition>
  <arm_group>
    <arm_group_label>2 week group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>3 week group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Capecitabine Oral Tablet [Xeloda]</intervention_name>
    <description>2 week group: capecitabine 1000mg/m2 d1-10; oxaliplatin 85mg/m2; q2w 3 week group: capecitabine 1000mg/m2 d1-14; oxaliplatin 130mg/m2; q3w</description>
    <arm_group_label>2 week group</arm_group_label>
    <arm_group_label>3 week group</arm_group_label>
    <other_name>oxaliplatin</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Carcinoma of the intestine confirmed histologically or cytologically&#xD;
&#xD;
          -  Radical surgical resection was performed after diagnosis and the post operative stages&#xD;
             were high-risk II or III patients&#xD;
&#xD;
          -  The ECOG PS score less than or equal to 2 points&#xD;
&#xD;
          -  No chemotherapy of any kind has been performed in the past&#xD;
&#xD;
          -  Neutrophils acuity 1.5x10e9/L, platelets more than 100x10e9/L, college blood red&#xD;
             protein more than 9g/dL&#xD;
&#xD;
          -  liver function transaminase is less than or equal to 2.5 ULN, alkaline phosphatase is&#xD;
             less than 2.5 ULN, and total bilirubin is less than 1.5 ULN&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients with unresectable CRC&#xD;
&#xD;
          -  Patients who have any form of chemotherapy before&#xD;
&#xD;
          -  Participating in or having participated in clinical studies of other drug&#xD;
&#xD;
          -  Patients have second primary malignant tumors of have other malignant tumors in the&#xD;
             past five years&#xD;
&#xD;
          -  There is evidence of allergic reaction to drugs in this study&#xD;
&#xD;
          -  A history of ischemic heart disease in the past 1 year or patients with high risk&#xD;
             factors for heart failure, or uncontrolled arrhythmias&#xD;
&#xD;
          -  Severe active inflammation, including tuberculosis and HIV&#xD;
&#xD;
          -  Long-term immunization or hormone therapy, except hormone replacement therapy at&#xD;
             physiological dose&#xD;
&#xD;
          -  Drug or alcohol addiction&#xD;
&#xD;
          -  Get pregnant or breastfeed&#xD;
&#xD;
          -  The investigator considers that the patient is not suitable for this clinical study&#xD;
             due to any clinical or laboratory abnormalities or compliance problems&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>First afflicated hospital of zhejiang university</name>
      <address>
        <city>Hangzhou</city>
        <state>Zhejiang</state>
        <zip>310000</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>May 27, 2018</study_first_submitted>
  <study_first_submitted_qc>June 19, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">June 21, 2018</study_first_posted>
  <last_update_submitted>August 24, 2021</last_update_submitted>
  <last_update_submitted_qc>August 24, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 25, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Zhejiang University</investigator_affiliation>
    <investigator_full_name>Weijia Fang, MD</investigator_full_name>
    <investigator_title>director</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colorectal Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Capecitabine</mesh_term>
    <mesh_term>Oxaliplatin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

